With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Press Releases


Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Crinetics announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. Quarterly highlights include the design of a Phase 3 program for paltusotine in acromegaly, which is expected to commence with the PATHFNDR-1 study in April.

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

Crinetics has closed its previously announced follow-on offering, proceeds from which will fund, in part, the continued development of paltusotine for acromegaly as well as other R&D programs.

Corporate Presentation

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact


Contact